Yoseph Shaaltiel is Executive VP & R&D at Protalix BioTherapeutics, Inc. (PLX). They have made 4 open-market trades across 1 company since 2007, most recently 2016-09-15.
CIK 0001385118
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $98K since 2007, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PLX | SELL · 10b5-1 | 2012-05-02 | 2012-05-04 | $7.13 | $2.1M | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-08-05 | 2010-08-09 | $7.00 | $371K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-06-21 | 2010-06-23 | $7.00 | $371K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-04-29 | 2010-05-03 | $7.00 | $89K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-04-14 | 2010-04-16 | $7.00 | $9K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-03-23 | 2010-03-25 | $7.05 | $2.7M | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2009-10-15 | 2009-10-19 | $9.41 | $941K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2009-07-06 | 2009-07-08 | $5.09 | $509K | -14.1% | +1.0% | +1.0% |
| PLX | SELL | 2009-05-13 | 2009-05-20 | $3.62 | $109K | -14.1% | +1.0% | +1.0% |
| PLX | SELL | 2009-03-13 | 2009-03-13 | $2.18 | $18K | -14.1% | +1.0% | +1.0% |
| PLX | BUY | 2007-12-17 | 2007-12-26 | $3.38 | $50K | -14.1% | +1.0% | +1.0% |
| PLX | BUY | 2007-12-05 | 2007-12-12 | $3.14 | $47K | -14.1% | +1.0% | +1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.